Compare Novavax Inc (NVAX) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Verizon Communications Inc — how do they compare? Novavax Inc trades at $12.84 (market cap $1.82B), while Verizon Communications Inc trades at $41.87 (market cap $192.57B). The key difference: Verizon Communications Inc is far larger — about 105.8× Novavax Inc's market cap, and Verizon Communications Inc pays a 6.11% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Verizon Communications Inc for 109 Days on average.
| NVAX | VZ | |
|---|---|---|
Market Cap | $1.82B | $192.57B |
Volume | 6,198,505 | 20,940,094 |
Sector | Health | Media |
52-Week High | $12.56 | $51.45 |
52-Week Low | $6.22 | $38.40 |
Typical Hold Time | 59 Days | 109 Days |
Enterprise Value | $1.39B | $379.28B |
Dividend Yield | — | 6.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Verizon (VZ) trades at $41.65, down 9% today, with bearish technical signals but solid fundamentals. The stock shows consistent earnings beats (Q4 2025-Q2 2026) and maintains strong cash flow ($37.1B operating cash flow in 2025). Recent news highlights Verizon's joint venture with AT&T and T-Mobile to expand coverage and the election of Charles Phillips to the board (GlobeNewsWire, September 29, 2026).
Outlook: Attractive for income investors with a 6.8% dividend yield and stable cash flow, but high debt ($144B total debt) and competitive pressures pose risks. Analyst consensus price target of $48.17 suggests 16% upside, though technical indicators remain bearish near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
